DDInter1152 DDInter1840
Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incid
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mycophenolic acid
Mycophenolic acid {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Cetirizine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Morphine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Azatadine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Cyclizine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carmustine
Carmustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Mephenytoin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Trabectedin (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Trabectedin (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trabectedin (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Mephenytoin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)